Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines

NCT04998136 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04998136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Asians With Obesity Diagnosed as BMI ≥ 25 kg/m2 According to Local Guidelines
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 15, 2022
Completion date
November 20, 2023
Enrollment
150 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obesity